https://www.selleckchem.com/pr....oducts/nigericin-sod
Inclusion of the pre-prodrug PR-104 into the treatment schedule provided significant additional activity, indicating proof-of-principle. Successful preclinical evaluation of a transferable gene that enables metabolism of both PET imaging agents (for vector visualisation) and prodrugs (for conditional enhancement of efficacy) is an important step towards the prospect of CDEPT entering clinical evaluation.Polygenic risk models have led to significant advances in understanding complex diseases and their clinical presentation.
Like
Comment
Share
